Given that the industry-tracking AdvisorShares Pure US Cannabis ETF (NYSEMKT: MSOS) is down by more than 60% in the last 12 months, dramatically underperforming the broader market's slump of 14.5%, it's safe to say that marijuana stock investors are likely feeling a bit down on their luck lately. The biggest change coming to cannabis stocks in the next couple of years is the possible advance of marijuana legalization in the U.S. and in the E.U. While the jury is still out on whether the federal government will legalize adult-use cannabis anytime soon, enterprising state legislatures are already forging ahead. While there's no timeline for when recreational sales will begin, Tilray Brands (NASDAQ: TLRY) is likely the best positioned to benefit since it's currently serving the country's medical cannabis market. Read More...
Given that the industry-tracking AdvisorShares Pure US Cannabis ETF (NYSEMKT: MSOS) is down by more than 60% in the last 12 months, dramatically underperforming the broader market’s slump of 14.5%, it’s safe to say that marijuana stock investors are likely feeling a bit down on their luck lately. The biggest change coming to cannabis stocks in the next couple of years is the possible advance of marijuana legalization in the U.S. and in the E.U. While the jury is still out on whether the federal government will legalize adult-use cannabis anytime soon, enterprising state legislatures are already forging ahead. While there’s no timeline for when recreational sales will begin, Tilray Brands (NASDAQ: TLRY) is likely the best positioned to benefit since it’s currently serving the country’s medical cannabis market.
Read More
Add Comment